摘要
目的:观察清热利湿活血方对慢性非细菌性前列腺炎(CAP)患者前列腺液中炎性因子、转化生长因子-β1(TGF-β1)、单核细胞趋化因子-1(MCP-1)、血小板衍生生长因子-BB(PDGF-BB)水平的影响。方法:选取湖州市中心医院泌尿外科2016年7月—2018年6月期间收治的CAP患者200例,按照随机数字表法分为观察组和对照组,每组100例。对照组给予盐酸坦索罗辛缓释胶囊0.2 mg口服,每天1次;观察组给予自拟清热利湿活血方,分早、晚各1次服用,每天1剂。2组患者均治疗1个疗程。比较2组治疗前后前列腺液中肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、TGF-β1、MCP-1、PDGF-BB水平,中医证候评分、美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)及疗效。结果:与同组治疗前比较,治疗后2组前列腺液中TNF-α、IL-6、IL-8、中医证候评分、NIH-CPSI评分、TGF-β1、MCP-1、PDGF-BB水平均下降(P<0.05)。治疗后与对照组比较,观察组前列腺液中TNF-α、IL-6、IL-8、TGF-β1、MCP-1、PDGF-BB水平及中医证候评分、NIH-CPSI均降低,差异均有统计学意义(P<0.05)。观察组有效率为90.00%,高于对照组的78.00%(P<0.05)。结论:清热利湿活血方可通过降低CAP患者前列腺液中TNF-α、IL-6、IL-8、TGF-β1、MCP-1及PDGF-BB水平,来改善患者中医证候和临床症状,以取得显著疗效,且安全性好。
Objective: To observe the effect of Qingre Lishi Huoxue prescription on levels of inflammatory factors,transforming growth factor β1(TGF-β1),monocyte chemoattractant protein-1(MCP-1) and platelet derived growth factor-BB(PDGF-BB) in prostatic fluid in patients with chronic abacterial prostatitis(CAP). Methods:A total of 200 cases of CAP patients treated in urinary surgery of Huzhou Central Hospital from July 2016 to June 2018 were divided into the control group and the observation group according to the random number table method,100 cases in each group. The control group was given0.2 mg of tamsulosin hydrochloride sustained-release capsules once a day;the observation group was given self-made Qingre Lishi Huoxue prescription one dose in a day,which was taken once in the morning and once in the evening. Both groups were treated for one course. The levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),interleukin-8(IL-8),TGF-β1,MCP-1 and PDGF-BB in prostatic fluid,the Chinese medicine symptom scores and the NIH-Chronic Prostatitis Symptom Index(NIH-CPSI) before and after treatment, as well as the curative effect in the two groups were compared.Results:Compared with those in the same group before treatment,the scores of TNF-α,IL-6,IL-8,Chinese medicine symptoms and NIH-CPSI as well as the levels of TGF-β1,MCP-1 and PDGF-BB in prostatic fluid in the two groups were decreased after treatment(P<0.05). After treatment,the levels of TNF-α,IL-6,IL-8,TGF-β1,MCP-1 and PDGF-BB in prostatic fluid and the scores of Chinese medicine symptoms and NIH-CPSI in the observation group were decreased when compared with those in the control group, differences being significant(P<0.05). The effective rate was 90.00% in the observation group,higher than that of 78.00% in the control group(P<0.05). Conclusion:Qingre Lishi Huoxue prescription can improve the Chinese medicine symptoms and clinical symptoms by reducing the levels of TNF-α,IL-6,IL-8,TGF-β1,MCP-1 and PDGF-BB in prostatic fluid of CAP patients,so as to achieve significant curative effect with good safety.
作者
施田力
黄小惠
肖鑫
周金标
SHI Tianli;HUANG Xiaohui;XIAO Xin;ZHOU Jinbiao
出处
《新中医》
CAS
2020年第14期88-91,共4页
New Chinese Medicine
基金
浙江省省级临床2017年度重点专项科研计划项目(2017C010034)。
